FGF23 Genotype

If you have a family history of unexplained bone pain, soft or bowed bones, short stature in childhood, or repeated stress fractures, this test asks a specific question: do you carry an inherited change in the FGF23 (fibroblast growth factor 23) gene that disrupts the hormone your body uses to regulate phosphate? Phosphate is a mineral your bones need to harden properly, and the FGF23 hormone is a central regulator of how much of it your kidneys keep versus flush out, working alongside parathyroid hormone.

Certain inherited mutations in this gene can produce a long-lasting form of the hormone that wastes phosphate through the urine, weakening bones over years. Standard lab panels rarely catch this. A routine metabolic panel may show a low phosphate level and nothing else, and many physicians will not connect that single number to a genetic cause without a targeted test.

What This Gene Does in Your Body

The FGF23 gene tells bone cells called osteocytes (and to a lesser extent osteoblasts) how to build the FGF23 hormone. Once released into the blood, the hormone travels to the kidneys and signals them to dump phosphate into the urine and to slow the activation of vitamin D. This keeps blood phosphate within a tight range. Under normal conditions, the body breaks down the hormone quickly by cleaving it at a specific recognition site, so the signal does not persist.

Specific mutations in the FGF23 gene, classically affecting the arginine residues at position 176 or 179 within the cleavage recognition site, make the hormone resistant to being broken down. When that happens, the kidneys keep getting the signal to flush out phosphate even when blood phosphate is already low. Over time, bones do not get enough phosphate to mineralize properly, and the result is a phosphate-wasting bone disorder known as autosomal dominant hypophosphatemic rickets, or ADHR.

Autosomal Dominant Hypophosphatemic Rickets

ADHR is the disorder most directly tied to inherited FGF23 gene mutations. It can show up as bowed legs and growth delays in childhood, or as bone pain, muscle weakness, and unexplained fractures in adulthood. Some carriers stay symptom-free for years and then develop bone problems triggered by other physiological changes such as iron deficiency or pregnancy. This delayed and variable presentation is why a genetic test can offer an answer that years of standard labs missed.

The defining biochemical pattern is a high or inappropriately normal level of circulating FGF23 hormone combined with a low blood phosphate. Studies of people with suspected FGF23-driven phosphate wasting have shown that an elevated intact FGF23 level, taken together with low phosphate, helps separate FGF23-mediated hypophosphatemia from other causes. That hormone signature is what your genetic result helps explain at its root, by pointing to the specific cause inside the gene itself.

Why a Genetic Cause Matters for Treatment

Confirming an inherited FGF23 mutation changes the conversation about treatment. Generic phosphate or vitamin D supplementation alone is often inadequate for FGF23-driven disease and can cause side effects. A targeted antibody therapy called burosumab is designed specifically to block the action of excess FGF23 hormone. In a randomized trial of adults with a related FGF23-driven condition (X-linked hypophosphatemia), burosumab corrected low phosphate levels in most participants and improved measures of stiffness and fracture healing over 24 weeks of treatment, with sustained benefit at 48 weeks. Improvements in pain were seen on secondary measures, although the primary pain endpoint did not reach statistical significance after adjustment for multiple comparisons.

Although those trials studied a different gene in the same hormone pathway, the underlying problem is similar: too much FGF23 signaling. Knowing that your phosphate wasting comes from an FGF23 gene mutation puts you in a position to ask your physician about whether targeted therapy is appropriate for you, rather than chasing symptoms with general supplements.

What Carrying a Variant Means for Your Result

Inheriting an FGF23 mutation does not guarantee you will develop the disease. ADHR is known for its incomplete and variable expression. Some carriers develop bone disease in childhood, others not until adulthood, and some never develop obvious symptoms. The likelihood of disease showing up in any given carrier is shaped by other factors, including iron status, pregnancy, and hormones. A positive result tells you that you carry the inherited risk; it does not tell you exactly when or how severely the disease will appear. This is why the result is most useful when paired with ongoing monitoring of phosphate, vitamin D, and bone markers over time.

Your Result Is Permanent

This is a one-time test. The variants you inherited at conception are the variants you will carry for life, so retesting the same gene is not useful unless the original variant call needs to be confirmed by a second laboratory method. The value of the test comes from acting on the result for the rest of your life, not from rechecking the number.

If your result identifies an FGF23 mutation linked to ADHR, the markers that should be tracked are the downstream signs of phosphate wasting, not the gene itself. A reasonable cadence for that follow-up is a baseline check of blood phosphate, vitamin D, alkaline phosphatase, and parathyroid hormone, then repeat checks every 6 to 12 months. If you are also tracking the FGF23 hormone level itself, plan on multiple measurements before drawing conclusions, because the intact form of the hormone shows high day-to-day variability within the same person (with reported within-person variation of roughly 12 to 18 percent), and a single reading can mislead.

When Results Can Be Misleading

Genetic test results can fall short in specific ways that are worth understanding before you act on a normal or unexpected report.

• Variant panel coverage: the assay only detects the specific changes it is designed to look for. A negative result does not rule out every rare or unusual variant in the FGF23 gene, including variants outside the classic cleavage site that have also been reported to cause disease. If clinical suspicion is high, broader sequencing may be needed.
• Variants of uncertain significance: sometimes a change is detected whose meaning is not yet known. This is not the same as a disease-causing mutation, and it should be interpreted with a specialist before driving treatment changes.
• Ethnic-specific allele patterns: the meaning of certain genetic findings can depend on ancestry. A variant common in one population may be very rare and more clinically significant in another.
• Confirmation may be warranted: if the result comes from a single-method assay and would change your treatment plan, a second confirmatory method, such as Sanger sequencing, is reasonable before committing to long-term therapy.

What to Do With an Out-of-Pattern Result

If you carry an FGF23 mutation linked to ADHR, the next step is not another genetic test. It is a focused biochemical workup to see whether the gene is currently driving disease in your body. That means ordering a blood phosphate, intact FGF23, 1,25-dihydroxyvitamin D, parathyroid hormone, alkaline phosphatase, and a urine phosphate-handling assessment. The combination of low blood phosphate, high or inappropriately normal FGF23, and low 1,25-dihydroxyvitamin D points to active phosphate wasting from the FGF23 pathway.

A referral to an endocrinologist or metabolic bone disease specialist is appropriate at this stage. They can decide whether targeted therapy is warranted and can coordinate imaging if bone deformities, fractures, or pseudofractures are suspected. A genetic counselor can help you talk through what the result means for biological relatives, including siblings, children, and parents, who may share the same inherited variant without knowing it.

If your result is negative but you still have unexplained low phosphate or bone disease, do not stop the workup. The FGF23 gene is one of several genes that can produce a similar clinical picture; conditions caused by PHEX, DMP1, ENPP1, and others (including SLC34A3, FAM20C, and SGK3) can also produce FGF23-driven phosphate wasting. A broader genetic evaluation may be the appropriate next move.